Literature DB >> 31481447

In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations.

Natalie S Nunnally1, Kizee A Etienne2, David Angulo3, Shawn R Lockhart2, Elizabeth L Berkow2.   

Abstract

Ibrexafungerp is a first-in-class glucan synthase inhibitor. In vitro activity was determined for 89 Candida glabrata isolates with molecularly identified FKS1 or FKS2 mutations conferring resistance to the echinocandins. All isolates were resistant to at least one echinocandin (i.e., anidulafungin, caspofungin, or micafungin) by broth microdilution. Results for ibrexafungerp were compared with those for each echinocandin. Ibrexafungerp had good activity against all echinocandin-resistant C. glabrata isolates.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Candida glabratazzm321990; FKSzzm321990; SCY-078; antifungal; echinocandins; ibrexafungerp; resistance

Mesh：

Substances：

Year:  2019        PMID： 31481447      PMCID： PMC6811432          DOI： 10.1128/AAC.01692-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates.

Authors:  Cristina Jiménez-Ortigosa; Padmaja Paderu; Mary R Motyl; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

2.  Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Authors:  A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

3.  In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris.

Authors:  Elizabeth L Berkow; David Angulo; Shawn R Lockhart
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

4.  De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance.

Authors:  Cristina Jiménez-Ortigosa; Winder B Perez; David Angulo; Katyna Borroto-Esoda; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

5.  Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.

Authors:  Michael A Pfaller; Shawn A Messer; Paul R Rhomberg; Katyna Borroto-Esoda; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

6.  Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.

Authors:  Alexander J Lepak; Karen Marchillo; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

7.  Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

Authors:  Barbara D Alexander; Melissa D Johnson; Christopher D Pfeiffer; Cristina Jiménez-Ortigosa; Jelena Catania; Rachel Booker; Mariana Castanheira; Shawn A Messer; David S Perlin; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

8.  Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.

Authors:  Cau D Pham; Naureen Iqbal; Carol B Bolden; Randall J Kuykendall; Lee H Harrison; Monica M Farley; William Schaffner; Zintars G Beldavs; Tom M Chiller; Benjamin J Park; Angela A Cleveland; Shawn R Lockhart
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

9.  Candidemia surveillance in Iowa: emergence of echinocandin resistance.

Authors:  Eiyu Matsumoto; Linda Boyken; Shailesh Tendolkar; Jennifer McDanel; Mariana Castanheira; Michael Pfaller; Daniel Diekema
Journal:  Diagn Microbiol Infect Dis       Date:  2014-03-01       Impact factor: 2.803

10.  A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis.

Authors:  E L Larkin; L Long; N Isham; K Borroto-Esoda; S Barat; D Angulo; S Wring; M Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191
View more
  13 in total

1.  Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action.

Authors:  Martin Hoenigl; Rosanne Sprute; Amir Arastehfar; John R Perfect; Cornelia Lass-Flörl; Romuald Bellmann; Juergen Prattes; George R Thompson; Nathan P Wiederhold; Mohanad M Al Obaidi; Birgit Willinger; Maiken C Arendrup; Philipp Koehler; Matteo Oliverio; Matthias Egger; Ilan S Schwartz; Oliver A Cornely; Peter G Pappas; Robert Krause
Journal:  Expert Opin Investig Drugs       Date:  2022-06-15       Impact factor: 6.498

2.  In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study.

Authors:  Guillermo Quindós; Katherine Miranda-Cadena; Rosario San-Millán; Katyna Borroto-Esoda; Emilia Cantón; María José Linares-Sicilia; Axel Hamprecht; Isabel Montesinos; Anna Maria Tortorano; Anna Prigitano; Matxalen Vidal-García; Cristina Marcos-Arias; Andrea Guridi; Ferran Sanchez-Reus; Jesús Machuca-Bárcena; Manuel Antonio Rodríguez-Iglesias; Estrella Martín-Mazuelos; Carmen Castro-Méndez; Leyre López-Soria; Alba Ruiz-Gaitán; Marcelo Fernandez-Rivero; Damaris Lorenzo; Javier Capilla; Antonio Rezusta; Javier Pemán; Josep Guarro; Joana Pereira; Célia Pais; Orazio Romeo; Guillermo Ezpeleta; Nerea Jauregizar; David Angulo; Elena Eraso
Journal:  Front Cell Infect Microbiol       Date:  2022-05-16       Impact factor: 6.073

Review 3.  Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections.

Authors:  Mahmoud Ghannoum; Maiken Cavling Arendrup; Vishnu P Chaturvedi; Shawn R Lockhart; Thomas S McCormick; Sudha Chaturvedi; Elizabeth L Berkow; Deven Juneja; Bansidhar Tarai; Nkechi Azie; David Angulo; Thomas J Walsh
Journal:  Antibiotics (Basel)       Date:  2020-08-25

Review 4.  Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor.

Authors:  Sabelle Jallow; Nelesh P Govender
Journal:  J Fungi (Basel)       Date:  2021-02-25

Review 5.  Novel antifungal agents in clinical trials.

Authors:  Samantha E Jacobs; Panagiotis Zagaliotis; Thomas J Walsh
Journal:  F1000Res       Date:  2021-06-28

Review 6.  Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis.

Authors:  Sarah E Murphy; Tihana Bicanic
Journal:  Front Cell Infect Microbiol       Date:  2021-12-14       Impact factor: 6.073

Review 7.  Investigational Agents for the Treatment of Resistant Yeasts and Molds.

Authors:  Garret T Seiler; Luis Ostrosky-Zeichner
Journal:  Curr Fungal Infect Rep       Date:  2021-05-28

Review 8.  Review on Current Status of Echinocandins Use.

Authors:  Martyna Mroczyńska; Anna Brillowska-Dąbrowska
Journal:  Antibiotics (Basel)       Date:  2020-05-02

9.  Low level of antifungal resistance of Candida glabrata blood isolates in Turkey: Fluconazole minimum inhibitory concentration and FKS mutations can predict therapeutic failure.

Authors:  Amir Arastehfar; Farnaz Daneshnia; Mohammadreza Salehi; Melike Yaşar; Tuğrul Hoşbul; Macit Ilkit; Weihua Pan; Ferry Hagen; Nazlı Arslan; Hatice Türk-Dağı; Süleyha Hilmioğlu-Polat; David S Perlin; Cornelia Lass-Flörl
Journal:  Mycoses       Date:  2020-08-05       Impact factor: 4.377

Review 10.  Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata.

Authors:  Ahmed Gamal; Sherman Chu; Thomas S McCormick; Katyna Borroto-Esoda; David Angulo; Mahmoud A Ghannoum
Journal:  Front Cell Infect Microbiol       Date:  2021-03-11       Impact factor: 5.293
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.